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Individual Study Methods and Cohort Descriptions 
 
The cohorts contributing to this study were general population samples. All participants provided written 
informed consent and studies were approved by their local Research Ethics Committees and/or Institutional 
Review Boards.  Summary demographic characteristics are listed in Table S2.  References for 
ascertainment methods and erythrocyte trait measurement for each participating study are given below. 
 
European Ancestry Cohorts 
 
Age, Gene/Environment Susceptibility‐Reykjavik Study (AGES)1,2 
 
Atherosclerosis Risk in Communities Study (ARIC)2,3 
 
Austrian Stroke Prevention Study  (ASPS) 4 
 
Baltimore Longitudinal Study of Aging (BLSA)5 
 
Coronary Artery Risk Development in Young Adults  (CARDIA)6 
 
Cardiovascular Health Study (CHS)2,7 
 
Framingham Heart Study (FHS)2,8 
 
Johns Hopkins Genetic Study of Atherosclerosis Risk (GeneSTAR)9–11 
 
Health, Aging, and Body Composition  (HealthABC)9,12 
 
Invecchiare in Chianti Study (InCHIANTI)5 
 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER/PHASE)13 
 
Rotterdam Study I (RS-I)2,14 
 
Rotterdam Study II (RS-II)14 
 
Rotterdam Study III (RS-III)14 
 
 
East-Asian Ancestry Cohorts 
 
The BioBank Japan Project  (RIKEN)15,16 
 
Asian Genetic Epidemiology Network (AGEN)17,18 
 
 
African-American  Ancestry  Cohorts 
 
Atherosclerosis Risk in Communities Study (ARIC)3,12,19 
 
Jackson Heart Study (JHS)12,19,20 
 
Coronary Artery Risk Development in Young Adults  (CARDIA)6,12,19 
 
Cardiovascular Health Study  (CHS)7 
 
Johns Hopkins Genetic Study of Atherosclerosis Risk  (GeneSTAR) 9–11 Page  2
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Health, Aging, and Body Composition  (HealthABC)9,12 
 
Women’s Health Initiative (WHI)12,19,21  
 
 
 
Replication CohortsGutenberg Health Study (GHS)22 
 
 Genes and Blood-Clotting Study (GBC)23 
 
 Netherlands Epidemiology of Obesity Study  (NEO)24 
 
 JUPITER Trial25 
 
HealthyAging in Neighborhoods of Diversity across the Life Span  (HANDLS)9,12 
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Supplemental Methods and Results 
Additional Human Replication Findings 
The discovery and replication results were meta-analysed separately for the EUR and AFR cohorts in 
METAL and with RE2, and as a further step, the combined METAL results were further meta-analysed with 
the EAS discovery data using METAL,MANTRA and RE2 methods. (Table S5). 
In both the replication and discovery samples, we verified the allele directions in the original input files to 
address the question whether allele flipping could account for the RBPMS finding for MCH. In our results 
rs2979489 only became genome-wide significant in the trans-ethnic meta-analysis; the individual ethnic-
specific results were not significant. We checked the allele frequencies in several 1000G panels. In all cases 
A was the most common allele and G the rarest, as is the case in our HapMap analyses. 
Pleiotropy analysis   
To further relate these findings in the rbpms gene family back to the human association data, we evaluated 
RBPMS in WBC traits and RBPMS2 in our RBC analyses and WBC traits. The purpose of this analysis was 
to explore possible pleiotropy which might suggest effects on an earlier hematopoietic progenitor cell. 
Variants in the RBPMS and RBPMS2 gene regions (+/- 50kb from exon borders) showed no association with 
WBC traits in a trans-ethnic analysis of the same cohorts.26  Further, there was no evidence of association 
with erythrocyte traits in the RBPMS2 region. Therefore, while there may be evidence of a functional class 
effect of the rbpms genes in the zebrafish experimental data, the human association data suggest that 
genetic variation in the RBPMS locus specifically influences erythrocyte traits in humans and that RBPMS is 
likely the true causal gene underlying this association. 
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Supplemental Figures 
Figure S1 
-log P value plots and varLD plots 
Regional association plots for loci identified by our trans-ethnic analysis. For each trait-locus identified in the 
MANTRA analyses, including the novel and previously known loci, we have plotted the individual ethnicity-
specific meta-analysis (METAL) results, the trans-ethnic fixed effects meta-analysis (METAL) and the 
Bayesian meta-analysis (MANTRA) results with SNPs colored according to the credible interval set for that 
region. Also shown for each region is the pair-wise LD correlation (varLD) and RNA expression of genes 
within the locus in erythroblast  cell lines).27 
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trait Region chr cyto Index SNP Total_gene Page
Hct 1 2 2p21 rs4953318 PRKCE 10
Hct 2 2 2q21 rs6430549 ACMSD 11
Hct 3 4 4q12 rs218237 KIT 12
Hct 4 4 4q21 rs1398018 SHROOM3 13
Hct 5 6 6p22 rs1800562 HFE 14
Hct 6 6 6q23 rs9399137 HBS1L 15
Hct 7 7 7q22 rs2075672 ACTL6B 16
Hct 8 7 7q31 rs2299433 MET 17
Hct 9 7 7q36 rs10224210 PRKAG2 18
Hct 10 9 9q34 rs495828 ABO 19
Hct 11 10 10q21 rs16926246 HK1 20
Hct 12 12 12q24 rs3184504 SH2B3 21
Hct 13 15 15q24 rs4886755 NRG4 22
Hct 14 17 17q21 rs241030 CRHR1 23
Hct 15 22 22q12 rs2413450 TMPRSS6 24
Hct 16 22 22q13 rs5765524 FBLN1 25
Hb 1 2 2p21 rs4953318 PRKCE 27
Hb 2 3 3q29 rs12632706 TFRC 28
Hb 3 4 4q12 rs170117 KIT 29
Hb 4 6 6p22 rs1800562 HFE 30
Hb 5 6 6p21 rs412657 NOTCH4 31
Hb 6 7 7q22 rs1617640 EPO 32
Hb 7 7 7q31 rs2299433 MET 33
Hb 8 7 7q36 rs10480299 PRKAG2 34
Hb 9 9 9q34 rs495828 ABO 35
Hb 10 10 10q21 rs16926246 HK1 36
Hb 11 12 12q24 rs11066301 PTPN11 37
Hb 12 15 15q24 rs4886755 NRG4 38
Hb 13 16 16p13 rs2562181 MPG 39
Hb 14 17 17q21 rs241030 CRHR1 40
Hb 15 22 22q12 rs4820268 TMPRSS6 41
MCHC 1 1 1q23 rs2479868 SPTA1 43
MCHC 2 6 6p22 rs198846 HIST1H1T 44
MCHC 3 6 6q23 rs9376090 HBS1L 45
MCHC 4 8 8p11 rs4737009 ANK1 46
MCHC 5 12 12q24 rs671 NA 47
MCHC 6 16 16p13 rs7197554 C16orf35 48
MCHC 7 16 16q24 rs2608604 CDT1 49
MCHC 8 22 22q12 rs2413450 TMPRSS6 50
MCH 1 1 1q31 rs12127588 PTPRC 52
MCH 2 2 2p16 rs13019832 BCL11A 53
MCH 3 3 3p24 rs2060597 PLCL2 54
MCH 4 3 3p24 rs1505307 THRB 55
MCH 5 3 3q23 rs6791816 ATR 56
MCH 6 3 3q29 rs9859401 TFRC 57
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MCH 7 4 4q12 rs218237 KIT 58
MCH 8 5 5p15 rs2736100 TERT 59
MCH 9 6 6p22 rs1800562 HFE 60
MCH 10 6 6p21 rs9349205 CCND3 61
MCH 11 6 6q21 rs9400273 CCDC162P/CD164 62
MCH 12 6 6q23 rs7776054 HBS1L 63
MCH 13 6 6q24 rs592423 CITED2/LOC655434 64
MCH 14 7 7p12 rs12669559 IKZF1 65
MCH 15 7 7q22 rs12532878 MOSPD3 66
MCH 16 8 8p21 rs2076940 XPO7 67
MCH 17 8 8p12 rs2979489 RBPMS 68
MCH 18 9 9p24 rs10758656 RCL1/MIR101-2 69
MCH 19 10 10q11 rs11239550 08-mrt 70
MCH 20 10 10q11 rs17720193 NA 71
MCH 21 12 12p13 rs7309743 CCND2 72
MCH 22 12 12q24 rs2074356 NA 73
MCH 23 14 14q23 rs7155454 FNTB/MIR4706 74
MCH 24 15 15q22 rs7165102 C15orf44 75
MCH 25 16 16p13 rs1122794 ITFG3 76
MCH 26 17 17q11 rs9892942 ERAL1 77
MCH 27 19 19p13 rs8887 KIAA1881/PLIN4 78
MCH 28 19 19p13 rs2242517 GCDH 79
MCH 29 20 20q13 rs737092 RBM38 80
MCH 30 22 22q12 rs2413450 TMPRSS6 81
MCV 1 1 1q23 rs12041363 OR10R2 83
MCV 2 1 1q31 rs1036332 PTPRC/LOC100131234 84
MCV 3 1 1q44 rs3811444 TRIM58 85
MCV 4 2 2p25 rs10929547 ID2 86
MCV 5 2 2p16 rs13027161 BCL11A/MIR4432 87
MCV 6 3 3p24 rs9821630 PLCL2 88
MCV 7 3 3p24 rs1505307 THRB 89
MCV 8 3 3q23 rs6780250 ATR 90
MCV 9 3 3q29 rs3893275 ZDHHC19 91
MCV 10 4 4q12 rs218237 KIT 92
MCV 11 5 5p15 rs2736100 TERT 93
MCV 12 6 6p22 rs198833 HIST1H1T 94
MCV 13 6 6p21 rs9349205 CCND3 95
MCV 14 6 6q21 rs9374080 CD164/CCDC162P 96
MCV 15 6 6q23 rs7776054 HBS1L 97
MCV 16 6 6q24 rs592423 CITED2/LOC645434 98
MCV 17 6 6q26 rs381500 QKI 99
MCV 18 7 7p12 rs12718598 IKZF1 100
MCV 19 7 7q22 rs7385804 TFR2 101
MCV 20 8 8p21 rs10503716 XPO7 102
MCV 21 8 8p12 rs2979489 RBPMS 103
MCV 22 9 9p24 rs10758658 RCL1/MIR101-2 104
MCV 23 9 9q34 rs8176749 ABO 105
MCV 24 10 10q11 rs963029 08-mrt 106
MCV 25 12 12p13 rs11611647 CCND2 107
MCV 26 12 12q24 rs2074356 NA 108
MCV 27 14 14q23 rs726668 MAXMIR4706 109
MCV 28 15 15q22 rs7176565 DENND4A/MIR4511 110
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MCV 29 16 16p13 rs13336641 NA 111
MCV 30 17 17q11 rs12325788 TRAF4 112
MCV 31 18 18q21 rs9949494 C18orf25 113
MCV 32 19 19p13 rs8887 KIAA1881/PLIN4 114
MCV 33 19 19p13 rs9384 GCDH 115
MCV 34 20 20q11 rs6121246 FKHL18/FOXS1 116
MCV 35 20 20q13 rs737092 RBM38 117
MCV 36 22 22q11 rs4820091 UBE2L3 118
MCV 37 22 22q12 rs5754115 FBXO7 119
MCV 38 22 22q12 rs2413450 TMPRSS6 120
MCV 39 22 22q13 rs140522 LOC440836/ODF3B 121
RBC 1 2 2p21 rs4952800 PRKCE 123
RBC 2 4 4p14 rs3860068 TMEM156 124
RBC 3 4 4q12 rs218237 KIT 125
RBC 4 6 6p21 rs9349205 CCND3 126
RBC 5 6 6q21 rs9400273 CD164/CCDC162P 127
RBC 6 6 6q23 rs9376090 HBS1L 128
RBC 7 6 6q24 rs592423 CITED2/LOC645434 129
RBC 8 7 7q22 rs2075672 ACTL6B 130
RBC 9 9 9p24 rs10758656 RCL1/MIR101-2 131
RBC 10 9 9q34 rs579459 ABO 132
RBC 11 12 12p13 rs7309743 CCND2 133
RBC 12 16 16p13 rs13339636 NA 134
RBC 13 17 17q21 rs2732706 LRRC37A 135
RBC 14 19 19p13 rs17706531 GCDH 136
RBC 15 22 22q13 rs12148 SCO2 137
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